α-干扰素、拉米夫定治疗慢性乙型肝炎临床观察

目的探讨干扰素（IFN-α2b）单用及联合应用拉米夫定对慢性乙型肝炎（CHB）的治疗效果和不良反应。方法66例CHB患者随机分为联合组与干扰素组。联合组33例，采用IFN—α2b和拉米夫定联合治疗；干扰素组33例，单用IFN-α2b治疗。疗程均为12月。结果联合组与干扰素组在治疗后和停药12个月时血清谷丙氨酸转移酶水平均较治疗前明显下降（P〈0、02）。停药12月HBeAg／抗-HBe转换率分别为41，47％和26、33％（P〉0．1），停药12月HBVDNA阴转率分别为69．70％和36．47％（P〈0、01）。86，57％的患者注射IFN-α2b后出现短暂发热等流感样症状，2组不良反应发生率无明显不同。结论IFN-α2b单独或联合拉米夫定治疗CHB均可取得较好的疗效；但联合组停药12月后HBVNDA阴转率明显高于干扰素组。

Clinical Evaluation of Lamivudine in Combination with Interferon A for Chronic Hepatitis B

Objective To observe the efficiency and safety of interferon-α2b（IFN-α2b） combined with Lamivudine for chronic hepatitis B. Methods Sixty-six patients with chronic hepatitis B were randomly divided into 2 groups. The observation group （n = 33 ） was administered with in IFN-α2b combined with Lamivudine,whereas the control group（ n = 33 ） only with IFN-α2b. The period of treatment was 12 months. Results The serum alanine aminotransferase level decreased significantly both groups （P〈0.02） at the end of treatment and 12 months later. The disappearance rates of HBeAg were 41.47% in the observation group and 26.33% in the control group respectively（P 〉0.1 ） ,and the clearance rates of HBV DNA were 69.70% in the obser- vation group and 36.47% in the control group respectively（ P 〈0.01 ） 12 months after stopping administering. Influenza-llke symptoms were observed in 86.57% of the patients treated with IFN-α2b. There was no obvious difference in the rate of side effects in both groups. Conclusions The IFN-α2b or IFN-α2b combined with Lamivudine is efficient for patients with chronic hepatitis B. The HBV DNA clearance effect by combination treatment is better than IFN-α2b treatment alone.